TOKYO (Reuters) – Fujifilm Holdings Corp said on Wednesday that late-stage research on the antiviral drug Avigan showed the drug shortens the recovery time for patients with mild symptoms of COVID-19.
A phase 3 clinical trial in 156 patients in Japan showed that those who received the drug improved after 11.9 days, compared to 14.7 days for the placebo group. The results of the study conducted by Fujifilm subsidiary Toyama Chemical were statistically significant, the company said in a press release.
Fujifilm Tokyo shares rose more than 4% to a four-month high.
Fujifilm said it will conduct further analysis of the test results and will try to apply for Avigan registration for the treatment of COVID-19 in October.
(Rocky Swift and Chris Gallagher in Tokyo, translated by Olga Devyatiarova. Editor Anna Kozlova)